Skip to content

Double-blind, randomized, placebo-controlled study of Leriglitazone in pediatric Rett Syndrome

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514684-26-00
Acronym
MT-2-04
Enrollment
24
Registered
2024-10-08
Start date
2024-10-29
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rett Syndrome

Brief summary

Safety and tolerability will be assessed informally based on summary statistics calculated for TEAEs, SAEs and other safety assessments and considerations

Detailed description

Change from baseline in Rett Syndrome Behavior Questionnaire (RSBQ), total score and each subscore., Change from baseline in Vineland Adaptative Behavior Scale (VABS), total score., Change from baseline in Rett Syndrome Motor Evaluation Scale (RESMES), total score., Change from baseline in Communication and Symbolic Behaviour Scales - Developmental Profile - Infant Toddler (CSBS-DP-IT), total score., Change from baseline in Mac Arthur I and II (reported according to age group), total score., Change from baseline in Clinical Global Impression-Severity (CGI-S), total score., Change from baseline in Clinical Global Impression-Improvement (CGI-I), total score., Change from baseline in Rett Syndrome Caregiver Burden Inventory (RTT-CBI), total score., Number of seizures per week recorded in the diary., Number of apnea episodes per week recorded in the diary., Number of hyperventilation episodes per week recorded in the diary., Predicted area under the plasma concentration versus time curve (AUC) and maximum observed plasma concentration (Cmax) for leriglitazone., Minimum observed plasma concentration (Cmin) for leriglitazone and M3., Metabolic ratio.

Interventions

DRUGThe min-102 placebo is supplied as an oral suspension with similar appearance to min-102 drug product. min-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose

Sponsors

Minoryx Therapeutics S.L.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Safety and tolerability will be assessed informally based on summary statistics calculated for TEAEs, SAEs and other safety assessments and considerations

Secondary

MeasureTime frame
Change from baseline in Rett Syndrome Behavior Questionnaire (RSBQ), total score and each subscore., Change from baseline in Vineland Adaptative Behavior Scale (VABS), total score., Change from baseline in Rett Syndrome Motor Evaluation Scale (RESMES), total score., Change from baseline in Communication and Symbolic Behaviour Scales - Developmental Profile - Infant Toddler (CSBS-DP-IT), total score., Change from baseline in Mac Arthur I and II (reported according to age group), total score., Change from baseline in Clinical Global Impression-Severity (CGI-S), total score., Change from baseline in Clinical Global Impression-Improvement (CGI-I), total score., Change from baseline in Rett Syndrome Caregiver Burden Inventory (RTT-CBI), total score., Number of seizures per week recorded in the diary., Number of apnea episodes per week recorded in the diary., Number of hyperventilation episodes per week recorded in the diary., Predicted area under the plasma concentration versus time curve (

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026